Benzodiazepines are among the most familiar medications in psychiatry. Alprazolam, lorazepam, clonazepam and diazepam are prescribed for panic attacks, generalized anxiety, insomnia and the acute distress that follows a crisis. They work quickly, and for many people they work well in the short term.
The puzzle that interests psychologists is what happens next. A drug taken to relieve anxiety can, over weeks and months, leave a person more anxious than before, unable to stop without feeling ill, and convinced that the medication is the only thing holding them together. Understanding why requires looking at the brain’s inhibitory system, the principles of learning, and the way a symptom and its treatment can become tangled together.
What Benzodiazepines Do in the Brain
The brain runs on a balance between excitation and inhibition. The main inhibitory neurotransmitter is gamma-aminobutyric acid, or GABA. When GABA binds to its receptor, the receptor opens a channel that lets chloride ions into the neuron, which makes the cell less likely to fire. Anxiety, in broad terms, involves circuits that are firing too readily.
Benzodiazepines do not add GABA to the brain. They bind to a separate site on the GABA-A receptor and change its shape so that the GABA already present works more efficiently. Pharmacologists call this positive allosteric modulation. The result is a rapid, dose-dependent quieting of neural activity, which the person experiences as calm, drowsiness and muscle relaxation.
This is also why the drugs are so widely used. According to the U.S. Food and Drug Administration, an estimated 92 million benzodiazepine prescriptions were dispensed from outpatient pharmacies in 2019, and about half of patients receiving oral benzodiazepines in 2018 were given them for two months or longer.
Tolerance: The Brain Pushes Back
Homeostasis is the tendency of biological systems to restore a set point when something disturbs it. If a drug is constantly amplifying inhibition, the brain adapts. Research on chronic benzodiazepine exposure describes several adaptations, including changes in the number and subunit composition of GABA-A receptors, weaker coupling between the drug’s binding site and the GABA site, and compensatory increases in excitatory glutamate signaling.
The behavioral consequence is tolerance: the same dose produces less effect. Sedation and the anti-anxiety effect tend to fade at different rates, and people often notice that a dose that once brought relief now merely keeps them level. In 2020 the FDA required an updated boxed warning on the entire class to describe the risks of abuse, misuse, addiction, physical dependence and withdrawal, noting that dependence can begin as early as days to weeks after starting.
Rebound Anxiety and the Withdrawal Cycle
Once the brain has recalibrated toward less inhibition, removing the drug reveals the adjustment. The excitatory changes are no longer being masked, so the nervous system overshoots. The person experiences rebound anxiety, which is anxiety that returns more intensely than the original symptoms, along with insomnia, tremor, irritability, sensory hypersensitivity and, in severe cases, seizures.
Rebound is easy to misread. Someone who feels a wave of dread a few hours after a missed dose reasonably concludes that their underlying disorder is worse than they thought. In fact they may be feeling interdose withdrawal, which is especially common with short-acting agents like alprazolam. The medication is treating a problem it is partly creating.
Why Stopping Suddenly Is Dangerous
The same homeostatic adjustment that produces rebound anxiety makes abrupt discontinuation risky. The FDA’s warning states plainly that stopping benzodiazepines suddenly or reducing the dose too quickly can cause withdrawal reactions, including seizures, that can be life-threatening. Delirium and severe agitation are also possible, particularly after high doses or long use.
Combining benzodiazepines with other sedatives compounds the danger. The National Institute on Drug Abuse reports that in 2021, nearly 14 percent of overdose deaths involving opioids also involved benzodiazepines, because both classes suppress breathing. A Centers for Disease Control and Prevention analysis found that from the second quarter of 2019 to the second quarter of 2020, deaths involving illicit benzodiazepines, often counterfeit pills, rose by more than 500 percent.
Because of these risks, quitting is a medical process rather than an act of willpower. For someone who has taken high doses for a long time, or who is also using alcohol or opioids, that process often begins with medically supervised detoxification and continues in a structured program. Treatment centers that handle both the medical taper and the underlying anxiety exist across the country; in the Midwest, for example, programs like Radix Recovery in Cedar Rapids, Iowa pair supervised detox and residential care with therapy for co-occurring anxiety disorders. When evaluating any program, a useful question is whether it treats the anxiety as its own diagnosis rather than as a side effect of the taper.
How Learning Reinforces Dependence
Psychology adds a second layer to the pharmacology. Operant conditioning describes how behavior is shaped by consequences. Taking a pill that removes an unpleasant state is negative reinforcement, and negative reinforcement is a powerful teacher. Each time a dose ends a surge of panic or a withdrawal symptom, the pill-taking response is strengthened.
Classical conditioning contributes as well. The bottle, the bedtime routine, the feeling of a racing heart before a meeting all become cues that predict relief and trigger the urge to use. Cognitively, people develop what therapists call safety behaviors: the belief that they cannot board a plane, give a presentation or sleep without the drug. That belief prevents the person from ever discovering that they could cope, which is precisely the discovery that cognitive behavioral therapy for anxiety is designed to produce.
None of this requires a person to be seeking a high. Most people who become dependent on prescribed benzodiazepines take them as directed. Physical dependence and addiction overlap but are not identical, and the distinction matters for how treatment is framed.
What a Supervised Taper Looks Like
In 2025, ten medical organizations, including the American Psychiatric Association and the American Society of Addiction Medicine, published a joint clinical practice guideline on benzodiazepine tapering. It recommends dose reductions of roughly 5 to 10 percent every two to four weeks, generally not exceeding 25 percent in any two-week period, with the pace tailored to the individual. For people who have taken high doses for years, a full taper may take months or longer.
The guideline also recommends offering psychosocial interventions during the taper, especially cognitive behavioral therapy. This is where the psychology and the pharmacology meet. As the dose falls, anxiety symptoms often rise temporarily, and without new skills the person is likely to return to the pill. Exposure exercises, cognitive restructuring and relaxation training give them an alternative response and begin to dismantle the safety behaviors that dependence built.
Treating the Anxiety That Started It
Anxiety disorders are common. The National Institute of Mental Health estimates that about 19 percent of U.S. adults meet criteria for an anxiety disorder in a given year. Most of those people never develop a problem with benzodiazepines, and the medications remain useful for short-term and specific situations.
The lesson from this corner of psychopharmacology is more specific. A drug that produces relief by amplifying inhibition invites the brain to adapt, and a behavior that produces relief invites the mind to repeat it. When both processes run for long enough, anxiety and its remedy fuse. Separating them again is possible, but it takes a slow taper, careful medical oversight and treatment aimed at the anxiety itself, not just at the drug.